4.5 Article

Differential neuropsychological outcomes following targeted responsive neurostimulation for partial-onset epilepsy

Journal

EPILEPSIA
Volume 56, Issue 11, Pages 1836-1844

Publisher

WILEY
DOI: 10.1111/epi.13191

Keywords

Epilepsy; Brain stimulation; Naming; Memory

Funding

  1. NeuroPace, Inc.
  2. NeuroPace
  3. Supernus
  4. Patient-Centered Outcomes Research Institute (PCORI)
  5. National Institutes of Health (NIH)
  6. NIH/NINDS [2U01-NS038455-11A1]
  7. NIH [R01NS076665-01A1, PC0RI 527]
  8. Eisai
  9. GW Pharmaceuticals
  10. Upsher Smith Laboratories
  11. UCB Pharma
  12. Dr. Meador's university

Ask authors/readers for more resources

ObjectiveResponsive neurostimulation decreases the frequency of disabling seizures when used as an adjunctive therapy in patients with medically refractory partial-onset seizures. The effect of long-term responsive neurostimulation on neuropsychological performance has not yet been established. MethodsNeuropsychological data were collected from subjects participating in the open-label arm of a randomized controlled trial of responsive neurostimulation with the RNS (R) System. Primary cognitive outcomes were the Boston Naming Test (BNT) and Rey Auditory Verbal Learning (AVLT) test. Neuropsychological performance was evaluated at baseline and again following 1 and 2 years of RNS System treatment. Follow-up analyses were conducted in patients with seizure onset restricted to either the mesial temporal lobe or neocortex. ResultsNo significant cognitive declines were observed for any neuropsychological measure through 2 years. When examined as a function of seizure onset region, a double dissociation was found, with significant improvement in naming across all patients (p < 0.0001), and for patients with neocortical seizure onsets (p < 0.0001) but not in patients with mesial temporal lobe (MTL) seizure onsets (p = 0.679). In contrast, a significant improvement in verbal learning was observed across all patients (p = 0.03), and for patients with MTL seizure onsets (p = 0.005) but not for patients with neocortical onsets (p = 0.403). SignificanceTreatment with the RNS System is not associated with cognitive decline when tested through 2 years. In fact, there were small but significant beneficial treatment effects on naming in patients with neocortical onsets and modest improvements in verbal learning for patients with seizure onsets in MTL structures. These results suggest that there are modest cognitive improvements in some domains that vary as a function of the region from which seizures arise.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychology, Clinical

Classification statistics of the Montreal Cognitive Assessment (MoCA): Are we interpreting the MoCA correctly?

Lauren N. Ratcliffe, Taylor McDonald, Brittany Robinson, John R. Sass, David W. Loring, Kelsey C. Hewitt

Summary: The study found that when using a cutoff score of <=26/30, White participants were classified more accurately than Black participants, leading to the suggestion of applying cutoff scores of <=25/30 for White individuals and <=22/30 for Black individuals. The research also emphasized the necessity of racially stratified population-based norms for Black participants with high misclassification rates.

CLINICAL NEUROPSYCHOLOGIST (2023)

Editorial Material Clinical Neurology

Pregnancy and Use of Antiseizure Medication

Julie Werenberg Dreier, Kimford J. J. Meador, Jakob Christensen

Summary: Antiseizure medications (ASMs) are commonly used by pregnant women for various conditions, but there is limited evidence on the cognitive risks of in utero exposure. Healthcare professionals and pregnant women face the challenge of balancing the risks and benefits of different treatments due to the lack of robust safety data. High-quality data on the safety of ASMs used in pregnancy are urgently needed, but randomized clinical trials are not possible in pregnant women. Therefore, evidence must be obtained from observational studies.

NEUROLOGY (2023)

Article Public, Environmental & Occupational Health

Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study

Shuang Wang, Kimford J. Meador, Jayne Pawasauskas, Adam K. Lewkowitz, Kristina E. Ward, Todd N. Brothers, Abraham Hartzema, Brian J. Quilliam, Xuerong Wen

Summary: This study aimed to assess the effects of buprenorphine and methadone treatment during early and late pregnancy on perinatal and pregnancy outcomes. The results showed that there were varying risks associated with the two treatments, with buprenorphine potentially being the preferred choice.

DRUG SAFETY (2023)

Article Clinical Neurology

Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy An Analysis of a Complex Comorbidity

Andres M. Kanner, Anita S. Saporta, Dong H. Kim, John J. Barry, Hamada Altalib, Hope Omotola, Nathalie Jette, Terence J. O'Brien, Siddhartha Nadkarni, Melodie R. Winawer, Michael Sperling, Jacqueline A. French, Bassel Abou-Khalil, Brian Alldredge, Martina Bebin, Gregory D. Cascino, Andrew J. Cole, Mark J. Cook, Kamil Detyniecki, Orrin Devinsky, Dennis Dlugos, Edward Faught, David Ficker, Madeline Fields, Barry Gidal, Michael Gelfand, Simon Glynn, Jonathan J. Halford, Sheryl Haut, Manu Hegde, Manisha G. Holmes, Reetta Kalviainen, Joon Kang, Pavel Klein, Robert C. Knowlton, Kaarkuzhali Krishnamurthy, Ruben Kuzniecky, Patrick Kwan, Daniel H. Lowenstein, Lara Marcuse, Kimford J. Meador, Scott Mintzer, Heath R. Pardoe, Kristen Park, Patricia Penovich, Rani K. Singh, Ernest Somerville, Charles A. Szabo, Jerzy P. Szaflarski, K. Liu Lin Thio, Eugen Trinka, Jorge G. Burneo

Summary: This study investigated the prevalence of mood, anxiety disorders, and suicidality in patients with newly diagnosed focal epilepsy. The results showed that 43.5% of patients had a psychiatric diagnosis, with 38.6% meeting the criteria for mood and/or anxiety disorders, and 21.6% reporting suicidal ideation. Major depressive disorders, bipolar disorders, panic disorders, and agoraphobia were associated with suicidality.

NEUROLOGY (2023)

Article Clinical Neurology

Multisite thalamic recordings to characterize seizure propagation in the human brain

Teresa Q. Wu, Neda Kaboodvand, Ryan J. McGinn, Mike Veit, Zachary Davey, Anjali Datta, Kevin D. Graber, Kimford J. Meador, Robert Fisher, Vivek Buch, Josef Parvizi

Summary: In patients with presumed temporal lobe epilepsy, the pulvinar subregion of the thalamus is found to be involved earlier and more prominently than the ANT in the propagation of seizures, according to a study. This research provides evidence for the feasibility and safety of personalized thalamic neuromodulation.

BRAIN (2023)

Editorial Material Clinical Neurology

Unjustified allegation on cancer risks in children of mothers with epilepsy taking high-dose folic acid during pregnancy-No proof of a causal relationship

Randi von Wrede, Juri-Alexander Witt, Stephane Auvin, Anita Devlin, Lieven Lagae, Anthony Marson, Kimford J. Meador, Terence J. O'Brien, Jun Park, Rainer Surges, Eugen Trinka, Samuel Wiebe, Christoph Helmstaedter

EPILEPSIA (2023)

Article Clinical Neurology

Depression and anxiety in caregivers of patients with functional seizures

Konstantinos Tsamakis, Diane L. Teagarden, Hannah K. Villarreal, Latasha Evans, Matthew L. Morton, Nicholas J. Janocko, Olivia Groover, Kelsey C. Hewitt, Michele E. Price, David W. Loring, Daniel L. Drane, Ioannis Karakis

Summary: This study aimed to evaluate the rates and determinants of depression and anxiety in caregivers of patients with functional seizures. The results showed that 96% of patients and 59% of caregivers had symptoms of anxiety and/or depression. The depression and anxiety levels of caregivers were strongly correlated with those of patients, and this occurrence may be related to factors such as patient gender, depression level, caregiver identity, and burden.

EPILEPTIC DISORDERS (2023)

Article Geriatrics & Gerontology

Telehealth equivalence of the Montreal cognitive assessment (MoCA): Results from the Emory healthy brain study (EHBS)

David W. W. Loring, James J. J. Lah, Felicia C. C. Goldstein

Summary: This study investigated potential differences between in-person cognitive testing and video telehealth administration of the Montreal Cognitive Assessment (MoCA). The results showed that there were no significant differences in MoCA scores between the two administration methods. Therefore, video telehealth administration can be confidently used for both clinical and research purposes.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2023)

Letter Clinical Neurology

Benefits and Risks of Periconceptional Folic Acid Supplementation

P. Emanuela Voinescu, Page B. Pennell, Kimford Meador

JAMA NEUROLOGY (2023)

Article Pharmacology & Pharmacy

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

R. L. Bromley, M. Bickle Graz, M. Bluett-Duncan, C. Chambers, P. Damkier, K. Dietrich, H. Dolk, K. Grant, S. Mattson, K. J. Meador, H. Nordeng, T. F. Oberlander, A. Ornoy, A. Revet, J. Richardson, J. Rovet, L. Schuler-Faccini, E. Smearman, V. Simms, C. Vorhees, K. Wide, A. Wood, L. Yates, E. Ystrom, T. A. Supraja, J. Adams

Summary: The study aims to achieve consensus on the core neurodevelopmental outcomes, optimize methodologies, and overcome barriers in conducting pregnancy pharmacovigilance studies with neurodevelopmental outcomes. The vision is to establish a comprehensive understanding of neurodevelopmental outcomes in pregnancy pharmacovigilance through a complementary set of studies.

FRONTIERS IN PHARMACOLOGY (2023)

Article Clinical Neurology

Later onset focal epilepsy with roots in childhood: Evidence from early learning difficulty and brain volumes in the Human Epilepsy Project

Jacob Pellinen, Heath Pardoe, Stefan Sillau, Sarah Barnard, Jacqueline French, Robert Knowlton, Daniel D. Lowenstein, Gregory Cascino, Simon Glynn, Graeme Jackson, Jerzy Szaflarski, Chris J. Morrison, Kimford Meador, Ruben Kuzniecky, Human Epilepsy Project Investigators

Summary: This study found that people with newly treated focal epilepsy and learning difficulties have lower brain tissue volume to intracranial volume, suggesting that developmental factors are an important marker of neuroanatomical changes in focal epilepsy. There were also independent associations between brain volume, age, and sex in the study population.

EPILEPSIA (2023)

Article Clinical Neurology

Utilization of Antiseizure Medications in Women of Childbearing Age With Epilepsy and Nonepilepsy Indications

Oluwadolapo D. Lawal, Kimford J. Meador, Anne L. Hume, Xuerong Wen

Summary: The study analyzed the pattern of antiseizure medication use in women of childbearing age with different indications, showing an increasing trend in the use of newer-generation ASMs and a decreasing trend in the use of older ASMs. The risk of teratogenicity associated with newer medications is largely unknown, emphasizing the importance of counseling and education in prescribing ASMs for women of childbearing age.

NEUROLOGY (2023)

Meeting Abstract Neurosciences

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

Rebecca Bromley, Miriam Bickle Graz, Matthew Bluett-Duncan, Christina Chambers, Per Damkier, Kim Dietrich, Helen Dolk, Kimberley Grant, Sarah Mattson, Kim Meador, Hedvig Nordeng, Tim Oberlander, Asher Ornoy, Alexis Revet, Jonathan Richardson, Joanne Rovet, Lavinia Schuler-Faccini, Erica Smearman, Victoria Simms, Charles Vorhees, Katrina Wide, Amanda Wood, Laura Yates, Evinid Ystrom, T. A. Supraja, Jane Adams

NEUROTOXICOLOGY AND TERATOLOGY (2023)

Article Clinical Neurology

Highlights From the Annual Meeting of the American Epilepsy Society 2022

Ignacio Valencia, Allyson L. Alexander, Danielle M. Andrade, Miguel Arevalo-Astrada, Clio Rubinos, Nancy Auer, Jacquelyn L. Bainbridge, Sallie A. Baxendale, Fabrice Bartolomei, Danielle A. Becker, Anne T. Berg, Andrea Bernasconi, Neda Bernasconi, Boris Bernhardt, Shivani Bhatnagar, Ingmar Bluemcke, Hal Blumenfeld, Gordon F. Buchanan, David E. Burdette, Jorge G. Burneo, Robyn M. Busch, Patrick Chauvel, Jeannie Chin, Lisa Clifford, Kelly R. Conner, Mark J. Cook, Jeannine Conway, Ramon Diaz-Arastia, Cornelia Drees, Jacqueline A. French, Taneeta Mindy Ganguly, Michael A. Gelfand, Tracy A. Glauser, Ezequiel Gleichgerrcht, Alica M. Goldman, Jorge Gonzalez-Martinez, Jean Gotman, Zachary Grinspan, Shanna Guilfoyle, Gita Gupta, Michael Hammer, Adam L. Hartman, Katie Hentges, R. Edward Hogan, Linda Huh, Ann Hyslop, Barbara Jobst, Colin B. Josephson, Sarah A. Kelley, Kelly Knupp, Matthias Koepp, Sanjeev Kothare, Esther Krook-Magnuson, Jasmine Kwasa, Maite La Vega-Talbott, Alice D. Lam, Jong Woo Lee, Daniel H. Lowenstein, Sarita Maturu, Luis Carlos Mayor, Carrie McDonald, Heather R. McKee, Guy M. McKhann, Kimford J. Meador, Heather C. Mefford, Elizabeth H. Michael, Mohamad A. Mikati, John J. Millichap, James W. Mitchell, Leah S. Myers, Dean Naritoku, Kerri L. Neville, Jeffrey Noebels, Terence J. O'Brien, Chima O. Oluigbo, Anup D. Patel, Milena K. Pavlova, Jeanne T. Paz, Page B. Pennell, M. Scott Perry, Piero Perucca, Asla Pitkaenen, Madona Plueger, Mary Jo Pugh, Mark Quigg, Shilpa B. Reddy, Christopher Ryan, Tamara S. Reynolds, Martha Sajatovic, Cesar Santana-Gomez, Linsday Schommer, Stephan Schuele, Renee A. Shellhaas, Daniel W. Shrey, Rani K. Singh, Michael R. Sperling, Saher Suleman, Jessica W. Templer, Maria Thom, Eugen Trinka, Sophia M. Varadkar, Naymee Velez-Ruiz, Jana Veliskova, Yuliya Voskobiynyk, Janelle L. Wagner, Jacy L. Wagnon, Claire Waller, Jill Waller, Zhong Irene Wang, Michelle W. Welborn, Elaine Wirrell, Barbara Jobst

Summary: The American Epilepsy Society Meeting 2022 in Nashville attracted over 6000 attendees and felt as busy as before the pandemic. The meeting provided a variety of symposia covering topics such as seizure generation, epilepsy pathophysiology, anti-seizure medications, and new treatment tools. It also included discussions on epilepsy comorbidities, practical issues in epilepsy care, and personal stories from patient advocates. Special lectures and smaller group sessions focused on specific areas of interest, and satellite symposia showcased the latest advancements in pharmaceutical and engineering fields.

EPILEPSY CURRENTS (2023)

Article Clinical Neurology

Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study

Kimford J. Meador, Morris J. Cohen, David W. Loring, Abigail G. Matthews, Carrie Brown, Chelsea P. Robalino, Angela K. Birnbaum, Paula E. Voinescu, Laura A. Kalayjian, Elizabeth E. Gerard, Evan R. Gedzelman, Julie Hanna, Jennifer Cavitt, Maria Sam, Jacqueline A. French, Sean Hwang, Alison M. Pack, Page B. Pennell, MONEAD Invest Grp

Summary: This study aimed to investigate the neurodevelopmental effects of fetal exposure to commonly used antiseizure medications, and found no difference in neurodevelopmental outcomes between children with fetal exposure to newer antiseizure medications compared with unexposed children.

LANCET NEUROLOGY (2023)

No Data Available